EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of COVID-19 Pandemic on Non-Small Cell Lung Cancer Care

YiYuan Zhai, Pooja Chopra, David Kang, Nicholas J Robert, Wei Zhang

Current Oncology · 2023

DOI: 10.3390/curroncol30010059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2023. Verfasst von YiYuan Zhai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Ontada, 6555 State Highway 161, Irving, TX 75039, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, COVID-19, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ontada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We assessed the impact of COVID-19 on healthcare visits, timing of stage IV NSCLC diagnosis and immunotherapy initiation, and rates of switching to extended dosing schedules of immunotherapies among patients with stage IV NSCLC. This retrospective study examined electronic health record data of adult patients receiving treatment for stage IV NSCLC within The US Oncology Network and Onmark. Endpoints were compared for February–July 2019 (before COVID) vs. February–July 2020 (during COVID). The study found rapid decreases in numbers of patients with clinic/vital visits, immunotherapy initiations, and new diagnoses of stage IV NSCLC during April–May 2020 vs. April–May 2019. The rate of delays of immunotherapy administrations and proportions of patients with such delays increased from February to March of 2020. These patterns may have resulted from the increase in COVID-19 cases during this period and the corresponding quarantine and lockdowns. However, when comparing pre COVID-19 and during COVID-19 for May and after, the differences in delay of immuno-oncology administrations became less marked, likely due to lifting of lockdowns. The rate of switching from shorter to longer dosing schedules increased from May–July 2020. This was mainly attributed to pembrolizumab, likely due to FDA approval of the pembrolizumab 6W dosing schedule in April 2020.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungCOVID-19Lung NeoplasmsAdultHumansRetrospective StudiesPandemicsCommunicable Disease Control

Stichwörter der Autor:innen

COVID-19 impact on cancer carecancer diagnosis delaycancer screening delaycancer treatment delayimmunotherapy dosing schedulenon-small cell lung cancer

Autor:innen und Institutionen

  • Ontada, 6555 State Highway 161, Irving, TX 75039, USA.

Förderung

  • Ontada

Zitieren

APA

Zhai, Y., Chopra, P., Kang, D., Robert, N. J., & Zhang, W. (2023). Impact of COVID-19 Pandemic on Non-Small Cell Lung Cancer Care. Current Oncology. https://doi.org/10.3390/curroncol30010059

Vancouver

Zhai Y, Chopra P, Kang D, Robert NJ, Zhang W. Impact of COVID-19 Pandemic on Non-Small Cell Lung Cancer Care. Current Oncology. 2023. doi:10.3390/curroncol30010059

BibTeX
@article{Zhai2023,
  author = {Zhai, YiYuan and Chopra, Pooja and Kang, David and Robert, Nicholas J and Zhang, Wei},
  title = {Impact of COVID-19 Pandemic on Non-Small Cell Lung Cancer Care},
  journal = {Current Oncology},
  year = {2023},
  doi = {10.3390/curroncol30010059}
}
Kostenlos starten →